Neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer: which patients benefit?
Level I
Where this comes from
- Record sourced from PubMed, PMID 23773558.
- Also identified by DOI 10.1016/j.eururo.2013.06.002.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Level I evidence supports neoadjuvant chemotherapy in the treatment of advanced bladder cancer. For the most benefit, it is suggested that neoadjuvant chemotherapy be restricted to patients with clinical T3 disease and/or clinical N+ disease.
Medical subject headings
- Cystectomy
- Neoadjuvant Therapy
- Patient Selection
- Urinary Bladder Neoplasms